Drugs / ITI-333
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05732194 | Jan → Sep 2023 | — | Intra-Cellular Therapies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05470101 | Jul 2022 → May 2023 | — | Intra-Cellular Therapies, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04934124 | Dec 2020 → Aug 2021 | — | Intra-Cellular Therapies, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITI-333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470101 ↗ |
| Route | Oral | “single oral dose” NCT04934124 ↗ |